XIAOMI-W
01810
BABA-W
09988
ALI HEALTH
00241
KUAISHOU-W
01024
BIDU-SW
09888
(FY)Mar 31, 2024 | (Q6)Sep 30, 2023 | (FY)Mar 31, 2023 | (Q6)Sep 30, 2022 | (FY)Mar 31, 2022 | (Q6)Sep 30, 2021 | (FY)Mar 31, 2021 | (Q6)Sep 30, 2020 | (FY)Mar 31, 2020 | (Q6)Sep 30, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Cash flow from operating activities | ||||||||||
Earning before tax | -952.75%-7.14B | ---- | 152.29%836.97M | ---- | -189.89%-1.6B | ---- | 93.65%1.78B | ---- | -39.76%919.46M | ---- |
Profit adjustment | ||||||||||
Interest (income) - adjustment | 23.91%-241.68M | ---- | 8.26%-317.62M | ---- | -9.30%-346.24M | ---- | -133.32%-316.79M | ---- | -28.86%-135.78M | ---- |
Interest expense - adjustment | 44.60%605.17M | ---- | 23.41%418.53M | ---- | -16.61%339.13M | ---- | -34.97%406.69M | ---- | 34.77%625.39M | ---- |
Investment loss (gain) | 321.26%6.89B | ---- | -59.94%1.63B | ---- | 2,181.97%4.08B | ---- | -224.84%-196.04M | ---- | -70.33%157.03M | ---- |
Attributable subsidiary (profit) loss | 106.73%29.13M | ---- | -1,548.93%-432.85M | ---- | -932.25%-26.25M | ---- | -103.24%-2.54M | ---- | 209.89%78.4M | ---- |
Revaluation surplus: | 93.01%-55.87M | ---- | -61.61%-799.27M | ---- | -304.61%-494.57M | ---- | 91.91%241.72M | ---- | 114.94%125.95M | ---- |
-Fair value of investment properties (increase) | 93.01%-55.87M | ---- | -61.61%-799.27M | ---- | -304.61%-494.57M | ---- | 91.91%241.72M | ---- | 114.94%125.95M | ---- |
Asset sale loss (gain): | --55K | ---- | ---- | ---- | -84.55%34K | ---- | -51.86%220K | ---- | -68.59%457K | ---- |
-Loss (gain) on sale of property, machinery and equipment | --55K | ---- | ---- | ---- | -84.55%34K | ---- | -51.86%220K | ---- | -68.59%457K | ---- |
Depreciation and amortization: | -2.66%216.77M | ---- | -0.65%222.71M | ---- | 9.94%224.16M | ---- | -6.35%203.9M | ---- | 11.15%217.73M | ---- |
-Depreciation | -2.66%216.77M | ---- | -0.65%222.71M | ---- | 9.94%224.16M | ---- | -6.35%203.9M | ---- | 11.15%217.73M | ---- |
Special items | --885.21M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Operating profit before the change of operating capital | -23.96%1.19B | ---- | -28.19%1.56B | ---- | 2.81%2.18B | ---- | 6.49%2.12B | ---- | 17.16%1.99B | ---- |
Change of operating capital | ||||||||||
Inventory (increase) decrease | 111.88%1.2M | ---- | -1,613.98%-10.07M | ---- | -58.39%665K | ---- | 8.63%1.6M | ---- | 119.55%1.47M | ---- |
Developing property (increase)decrease | -56.52%-1.11B | ---- | -2.23%-710.94M | ---- | 70.57%-695.42M | ---- | -17,911.22%-2.36B | ---- | 98.36%-13.12M | ---- |
Accounts receivable (increase)decrease | 26.00%-851.54M | ---- | -104.30%-1.15B | ---- | -2,459.28%-563.25M | ---- | 113.77%23.87M | ---- | -1,558.38%-173.32M | ---- |
Accounts payable increase (decrease) | 902.48%111.52M | ---- | 98.70%-13.9M | ---- | -199.83%-1.07B | ---- | 9,371.04%1.07B | ---- | 90.95%-11.59M | ---- |
Special items for working capital changes | -64.55%637.29M | ---- | 852.73%1.8B | ---- | -89.65%188.71M | ---- | 270.43%1.82B | ---- | 73.48%-1.07B | ---- |
Cash from business operations | -101.73%-25.48M | -502.49%-111.28M | 4,090.23%1.48B | 105.15%27.65M | -98.69%35.22M | -148.40%-537.35M | 271.12%2.68B | -26.13%1.11B | 121.98%721.8M | 149.59%1.5B |
Other taxs | -2.22%-3.09M | 69.42%-700K | 41.81%-3.02M | -341.89%-2.29M | -6,473.42%-5.19M | -360.30%-518K | 99.51%-79K | 104.62%199K | 47.02%-16.01M | -57.94%-4.31M |
Interest received - operating | 1,272.30%338.59M | 1,481.27%148.53M | 18.19%24.67M | 39.13%9.39M | 265.01%20.88M | -74.72%6.75M | -76.85%5.72M | 152.59%26.71M | -71.64%24.7M | -85.30%10.57M |
Interest paid - operating | -92.93%-1.12B | -95.67%-499.89M | -20.87%-580.71M | 3.33%-255.48M | -12.49%-480.45M | -21.90%-264.28M | 31.80%-427.11M | 37.45%-216.8M | -30.40%-626.23M | -39.66%-346.62M |
Net cash from operations | -188.40%-810.32M | -109.92%-463.35M | 313.39%916.62M | 72.25%-220.73M | -119.03%-429.55M | -186.43%-795.4M | 2,065.08%2.26B | -20.84%920.27M | 102.81%104.26M | 136.22%1.16B |
Cash flow from investment activities | ||||||||||
Dividend received - investment | ---- | ---- | ---- | ---- | --7.56M | ---- | ---- | ---- | --80.85M | --80.85M |
Loan receivable (increase) decrease | ---- | -81.53%-273M | ---- | -201.96%-150.39M | 312.43%266.51M | 731.17%147.51M | 107.43%64.62M | 87.86%-23.37M | -145.44%-869.81M | 22.04%-192.55M |
Purchase of fixed assets | 15.26%-46.07M | 58.52%-13.62M | 80.31%-54.36M | 83.81%-32.84M | -198.20%-276.14M | -525.78%-202.8M | -31.56%-92.6M | -44.39%-32.41M | 26.78%-70.39M | 49.12%-22.44M |
Sale of subsidiaries | ---379K | ---379K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Recovery of cash from investments | 17.50%340.58M | 2,248.16%125.69M | 209.19%289.84M | ---5.85M | ---265.46M | ---- | ---- | ---- | ---- | ---- |
Cash on investment | 83.93%-306K | 46.47%-5.13M | 94.74%-1.9M | 96.51%-9.59M | -59.65%-36.2M | -3,716.22%-274.81M | 96.65%-22.68M | 78.21%-7.2M | -3,489.40%-676.35M | 80.11%-33.05M |
Other items in the investment business | -123.50%-487.27M | ---- | ---218.02M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Net cash from investment operations | -1,343.42%-193.45M | 16.22%-166.45M | 105.12%15.56M | 39.82%-198.67M | -499.55%-303.73M | -424.15%-330.11M | 96.70%-50.66M | 62.33%-62.98M | -250.23%-1.54B | 63.43%-167.19M |
Net cash before financing | -207.68%-1B | -50.17%-629.79M | 227.12%932.18M | 62.74%-419.4M | -133.23%-733.29M | -231.29%-1.13B | 254.15%2.21B | -13.87%857.29M | 65.47%-1.43B | 127.15%995.36M |
Cash flow from financing activities | ||||||||||
New borrowing | 27.89%4.42B | 0.91%2.07B | -15.65%3.46B | -39.42%2.05B | 146.67%4.1B | 37,456.38%3.38B | -35.68%1.66B | -99.34%9M | -60.99%2.58B | -70.36%1.37B |
Refund | 21.39%-3.33B | 16.54%-1.33B | 6.42%-4.23B | 39.05%-1.6B | -81.01%-4.52B | -470.63%-2.62B | -272.98%-2.5B | 76.21%-459.5M | 72.07%-669.9M | -72.64%-1.93B |
Dividends paid - financing | ---- | ---- | ---- | ---- | ---53.75M | ---75.18M | ---- | ---- | 16.08%-36.64M | 42.19%-37.21M |
Absorb investment income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -88.26%4.54M |
Issuance expenses and redemption of securities expenses | ---- | ---- | ---- | ---- | ---- | ---- | -150.00%-250M | -150.00%-250M | 68.09%-100M | 68.70%-100M |
Other items of the financing business | -17.13%3.57M | -37.87%1.14M | 114.35%4.3M | 44.55%1.83M | -5.73%2.01M | 48.07%1.27M | -59.72%2.13M | --855K | -86.52%5.29M | ---- |
Net cash from financing operations | 239.88%1.09B | 63.35%729.52M | -62.33%-779.47M | -34.58%446.6M | 55.85%-480.17M | 197.38%682.63M | -161.10%-1.09B | -0.81%-701.02M | -54.44%1.78B | -122.05%-695.36M |
Effect of rate | -64.31%-5.25M | 57.33%-9.28M | -149.24%-3.19M | -939.03%-21.75M | -67.87%6.49M | -134.23%-2.09M | 526.60%20.19M | 491.23%6.12M | -24.16%-4.73M | -610.45%-1.56M |
Net Cash | -43.30%86.58M | 266.62%99.72M | 112.58%152.7M | 106.14%27.2M | -208.44%-1.21B | -383.40%-442.87M | 220.95%1.12B | -47.91%156.27M | 246.33%348.66M | 158.41%300M |
Begining period cash | 16.96%1.03B | 16.96%1.03B | -57.79%881.52M | -57.79%881.52M | 120.01%2.09B | 120.01%2.09B | 56.81%949.28M | 56.81%949.28M | -28.57%605.36M | -28.57%605.36M |
Cash at the end | 7.89%1.11B | 26.44%1.12B | 16.96%1.03B | -46.03%886.97M | -57.79%881.52M | 47.84%1.64B | 120.01%2.09B | 23.00%1.11B | 56.81%949.28M | 170.89%903.8M |
Cash balance analysis | ||||||||||
Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | Unqualified Opinion | -- | Unqualified Opinion | -- | Unaudited opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- |
Auditor | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.